➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Baxter
McKinsey
Johnson and Johnson
Moodys

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

SUMAVEL DOSEPRO Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Sumavel Dosepro, and when can generic versions of Sumavel Dosepro launch?

Sumavel Dosepro is a drug marketed by Endo Ventures Ltd and is included in one NDA. There are nine patents protecting this drug.

This drug has thirty-two patent family members in nine countries.

The generic ingredient in SUMAVEL DOSEPRO is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

US ANDA Litigation and Generic Entry Outlook for Sumavel Dosepro

A generic version of SUMAVEL DOSEPRO was approved as sumatriptan succinate by WEST-WARD PHARMS INT on February 6th, 2009.

  Start Trial

Drug patent expirations by year for SUMAVEL DOSEPRO
Drug Prices for SUMAVEL DOSEPRO

See drug prices for SUMAVEL DOSEPRO

Recent Clinical Trials for SUMAVEL DOSEPRO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Synteract, Inc.Phase 4
Zogenix, Inc.Phase 4

See all SUMAVEL DOSEPRO clinical trials

US Patents and Regulatory Information for SUMAVEL DOSEPRO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-002 Nov 26, 2013 DISCN Yes No   Start Trial   Start Trial   Start Trial
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SUMAVEL DOSEPRO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009   Start Trial   Start Trial
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009   Start Trial   Start Trial
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009   Start Trial   Start Trial
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009   Start Trial   Start Trial
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009   Start Trial   Start Trial
Endo Ventures Ltd SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
McKesson
Moodys
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.